Italian Tennis Star Jasmine Paolini Joins Amazfit as Latest Athlete Ambassador

 MILPITAS, Calif. - Tuesday, 18. February 2025 AETOSWire 

Paolini to Wear Amazfit Smart Wearables to Enhance Performance and Recovery.

Amazfit logo to appear on Paolini’s on-court apparel.

 

(BUSINESS WIRE)--Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), today announced the signing of Italian tennis sensation and World No. 4 Jasmine Paolini as its newest global athlete partner. As part of the multi-year agreement and official smart wearable partnership, Paolini will represent Amazfit by wearing the Amazfit logo and smartwatch on court and the brand’s fitness wearables, including Helio Ring, to track sleep and athletic recovery.

Paolini is the current Italian No. 1 and highest-ranked Italian singles player in WTA history. She reached both singles and doubles finals at the 2024 French Open and was a singles finalist at 2024 Wimbledon. Additionally, Paolini is the reigning Olympic gold medalist in doubles and holds two WTA singles and six doubles titles to her name.

“I’ve seen firsthand how tracking my performance and analyzing data during training is essential to competing at the highest level,” said Paolini. “As a tennis player, I’m constantly traveling, adjusting to new time zones, and pushing my body through intense matches and training sessions. With Amazfit’s smart wearables, I can monitor my recovery, sleep quality, and overall fitness in real time, ensuring I adapt quickly and stay at my best, no matter where I am. I’m thrilled to join the Amazfit family and take my game to the next level.”

With Amazfit’s advanced tracking technology, Paolini will gain deep insights into her training, health, and recovery—both on and off the court. By leveraging Amazfit’s smart wearables, she will be able to monitor key performance metrics, including heart health, sleep quality and exertion load, enabling her to optimize her preparation, recovery, and overall well-being.

Wayne Huang, Founder & CEO of Zepp Health, emphasized the importance of Paolini’s signing and the brand’s commitment to elite performance: "Jasmine Paolini’s incredible achievements and dedication to maximizing her performance align perfectly with Amazfit’s vision for advanced sports technology. We go beyond providing smartwatches—we are building a complete smart wearable ecosystem. From the Amazfit Helio Ring, which helps track recovery and sleep, to the latest nutrition management features in our app that support post-match recovery, our technology enables athletes to train smarter, recover more efficiently, and perform at their peak. With Paolini joining Amazfit, we not only support her journey at the highest level of tennis but also showcase how Amazfit’s smart wearable ecosystem empowers athletes and sports enthusiasts worldwide."

Paolini’s signing strengthens Amazfit’s growing roster of elite athletes, joining fellow Italian and European champion distance runner Yeman Crippa, Olympic gold medalist sprinter Gabby Thomas, HYROX World Champions Meg Jacoby and Hunter McIntyre, Olympic triathlete Morgan Pearson and Padel star Bea González.

Amazfit is committed to creating products that empower holistic health and well-being, and that healthy living requires balance across four key pillars of wellness: physical fitness, sleep, mindfulness and nutrition. Amazfit’s diverse product portfolio includes Active, Cheetah and T-Rex series performance smartwatches, Helio smart ring and the Zepp App, all designed to help athletes and health enthusiasts track and enhance their holistic health. The Zepp App’s latest Food Log feature, currently available in United States and scheduled to role out in other markets later this year, offers athletes like Paolini an unparalleled ability to bridge the gap between nutrition and fitness, ensuring peak performance and optimal recovery. Whether monitoring heart rate, tracking sleep cycles, or logging meals, Amazfit provides the insights needed to maintain a well-rounded approach to health and performance.

For more information, please visit Amazfit.com and follow us on Facebook, Instagram, Twitter and YouTube.

About Amazfit

Amazfit, a leading global smart wearable brand focused on health and fitness, is part of Zepp Health (NYSE: ZEPP), a health technology company. Offering a wide selection of smartwatches and bands, Amazfit's brand tagline "Discover Amazing", encourages individuals to break their barriers, and exceed expectations while finding joy in every moment.

Amazfit is powered by Zepp Health's proprietary health management platform that delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. With outstanding craftsmanship, Amazfit smartwatches have won many design awards, including the iF Design Award and the Red Dot Design Award.

Launched in 2015, Amazfit is today embraced by millions of users. Its products are available in more than 90 countries across the Americas, EMEA, and APAC regions. For more information about Amazfit, visit www.amazfit.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218222601/en/

Permalink

https://www.aetoswire.com/en/news/1802202544797

Contacts

MEDIA CONTACT

Mary Thompson Woodbury

mary.woodbury@zepp.com

Bentley Systems Issues Call for Nominations for the 2025 Going Digital Awards

 EXTON, Pa. - Monday, 17. February 2025 AETOSWire Print 

Winners to be Announced at the 2025 Year in Infrastructure Conference, Taking Place in Amsterdam on October 14-15

 

(BUSINESS WIRE)--Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced nominations are now open for the 2025 Going Digital Awards. This renowned global program recognizes the very best digital advancements in infrastructure delivery and performance. Independent jurors—consisting of thought leaders and experts in their field—select the winners from among the world’s most extraordinary infrastructure projects. The deadline for nominations is March 31, 2025.

Celebrating over 20 years, the awards program has recognized more than 5,250 of the world's most outstanding infrastructure projects. This global program is open to all Bentley software users and nominations are encouraged across a range of categories, encompassing all forms of infrastructure projects and stages—from design and construction to operations.

Three finalists will be chosen within each of the 12 award categories. Finalists will attend Bentley’s Year in Infrastructure conference and Going Digital Awards program in Amsterdam, October 14-15, 2025, as guests of Bentley. As part of the conference, finalists will win a trip to the Year in Infrastructure and Going Digital Awards to present their projects before an independent jury of industry peers and key members of the press. In addition to the juried awards, Bentley’s founders will honor select projects representing organizations or individuals making meaningful contributions to infrastructure advancement. Winners will be announced on October 15 during the Going Digital Awards ceremony.

The 2025 Going Digital Awards categories include:

Bridges and Tunnels​

Cities, Campuses, and Facilities

Construction​

Energy Production

Geospatial and Reality Modeling

Project Delivery​

Rail and Transit​

Roads and Highways​

Structural Engineering​

Subsurface Modeling and Analysis​

Transmission and Distribution​

Water and Wastewater​

Going Digital Awards projects will also be profiled in Bentley’s Infrastructure Yearbook, which is distributed to an international audience comprised of government officials, industry influencers, media, industry analysts, and Bentley users.

For more information about the 2025 Going Digital Awards program, or to nominate a project, visit the Going Digital Awards website.

# # #

About Bentley Systems

Bentley Systems (Nasdaq: BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, mining, and industrial facilities. Our offerings, powered by the iTwin Platform for infrastructure digital twins, include MicroStation and Bentley Open applications for modeling and simulation, Seequent’s software for geoprofessionals, and Bentley Infrastructure Cloud encompassing ProjectWise for project delivery, SYNCHRO for construction management, and AssetWise for asset operations. Bentley Systems’ 5,200 colleagues generate annual revenues of more than $1 billion in 194 countries.

© 2025 Bentley Systems, Incorporated. Bentley, the Bentley logo, Bentley Open, Bentley Infrastructure Cloud, AssetWise, iTwin, MicroStation, ProjectWise, SYNCHRO, and Seequent are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250217405555/en/

Permalink

https://www.aetoswire.com/en/news/1702202544747

Contacts

For more information, contact:

Press: Chris Phillips, PR@news.bentley.com

Investors: Eric Boyer, IR@bentley.com

ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b)

 (BUSINESS WIRE)--Today, a tribunal under the auspices of the International Chamber of Commerce (ICC) served a partial final award in a dispute between PharmaEssentia Corp. (“PharmaEssentia”) and AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in AOP Health’s favor. At the heart of the case were reciprocal claims for damages arising from a dispute regarding a licensing agreement between the parties.

The product in dispute

The conflict centers around ropeginterferon alfa-2b, a substance launched in 2019 and that AOP Health has developed into an innovative treatment (BESREMi®) for rare blood cancers, particularly polycythemia vera, through a comprehensive clinical trial program. This makes BESREMi® the best investigated interferon in clinical trials in this indication as documented in the major relevant guidelines1. AOP Health had acquired the rights for both BESREMi®’s development and commercialization in the European, Commonwealth of Independent States (CIS), and Middle Eastern markets from PharmaEssentia in 2009. In its sixth year after its approval by European Medicines Agency (“EMA”), AOP Health has successfully made BESREMi® available to an estimated 9,000 patients in AOP Health’s licensed territory.

First arbitration and set-aside proceedings

Since 2017, PharmaEssentia repeatedly sought to terminate its agreement with AOP Health regarding BESREMi®. In October 2020, an ICC Arbitral Tribunal ruled these attempts unjustified. AOP Health was awarded approx. EUR 143 million in damages for project delays caused by PharmaEssentia, while the latter´s counterclaims were dismissed.

PharmaEssentia’s 2021 application to set aside the award was rejected by the Frankfurt Higher Regional Court. Upon its subsequent appeal to the German Federal Supreme Court, the agreement’s validity and the dismissal of PharmaEssentia 's counterclaims was upheld. The German Federal Supreme Court found procedural flaws with respect to damage quantification of the awarded approx. EUR 143 million, impacting the damages awarded.

Second arbitration

In November 2020, PharmaEssentia initiated a legal action against AOP Health, alleging damage claims. AOP Health in turn claimed damages for delays in BESREMi®’s European approval caused by PharmaEssentia, and the misuse of AOP Health’s clinical trial data for PharmaEssentia’s US marketing authorization.

Result: partial final award in favor of AOP Health

While the partial final award rules in favor of AOP Health regarding PEC's intentional breaches and liability for several claims, the tribunal’s decision on the quantum of those claims is yet to be made.

AOP Health welcomes this decision. It will continue to supply patients in need of ropeginterferon alfa-2b (BESREMi®).

Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We are pleased that the ICC Arbitral Tribunal decided in our favor again. However, we still believe that an outcome benefiting the patients most can only be reached by finding a joint solution to not only overcome the past but also future challenges in our cooperation. We are willing to focus on the common objectives and not the differences.”

About BESREMi®

BESREMi® is the first interferon that was approved for polycythemia vera, a myelo­proliferative neoplasm (MPN), indicated in the European Union as monotherapy in adults for treatment of polycythemia vera without symptomatic enlarged spleen. Its overall safety and efficacy were demonstrated in multiple clinical studies.

BESREMi® (ropeginterferon alfa-2b) is a long-acting, mono-pegylated proline interferon (ATC L03AB15). It is administered once every 2 weeks initially, or up to every 4 weeks after stabilization of blood values. BESREMi® is designed to be self-administered subcutaneously with a pre-filled pen.

For the EMA Summary of Product Characteristics please visit: BESREMi®

About AOP Health

AOP Health is a global healthcare group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH ("AOP Health") is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine.

At the end of 2024, AOP Health received its first U.S. FDA approval for Rapiblyk™, a medication aimed at patients in intensive care units, thereby further strengthening its commitment to making therapies available for patients worldwide. The AOP Health Group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners.

With the claim "Needs. Science. Trust." the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the AOP Health Group’s actions.

___________________________

1 ELN Guideline (2022), NCCN Guideline (2024), Onkopedia Leitlinie (2023)

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250217280380/en/

Permalink

https://www.aetoswire.com/en/news/1702202544746

Contacts

Mag. Nina Roth

Nina.Roth@aop-health.com

+43-676-3131509

https://www.aop-health.com

Eurobank Collaborates with LTIMindtree for a Multi-Year Banking Technology Program

 PUNE, India & ATHENS, Greece 

Cements relationship with the opening of Global Delivery Center in Pune, India

(BUSINESS WIRE)--Eurobank S.A. (“Eurobank”), a subsidiary of “Eurobank Ergasias Services and Holdings S.A.” (“Eurobank Holdings”) a leading banking group in Athens, Greece and LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, have joined forces to initiate a multi-year mutually beneficial cooperation focused on enhancing customer experience by improving banking operations and building innovative IT services for Eurobank and its subsidiaries. The collaboration has been enabled by Fairfax Digital Services (A Fairfax Company) and will include the establishment of a Global Delivery Center in India.

Global Delivery Center, Pune – Executing a shared vision

Strengthening the commitment to innovation, customer experience, and excellence in banking technology, Eurobank & LTIMindtree, powered by Fairfax Digital Services, officially inaugurated their new Global Delivery Center at the LTIMindtree office today in Pune, India. The Global Delivery Center is yet another testimony to the strong economic ties between Greece & India. Alongside the recently established LTIMindtree Greece office, this center will drive technology modernisation, digital innovation as well as enhance and maintain critical banking applications. This initiative will empower Eurobank Group to effectively meet growing customers' demands as it expands its services.

Empowering Eurobank Group - Harnessing Next-Gen IT Solutions to enhance customer experience

As part of the multi-year relationship, LTIMindtree has been selected as the Services Partner for Eurobank Luxembourg’s Temenos implementation program, providing maintenance, data migration, quality assurance, and post-production support services to the bank. LTIMindtree will help drive innovation and modernise the technology infrastructure for Eurobank Group, in Cyprus, Luxembourg and Greece. The collaboration will enable both companies to leverage the power of LTIMindtree’s innovative technology and data solutions to drive significant improvements in customer experience and operational efficiency.

Deputy Chief Executive Officer (CEO), Group Chief Operating Officer (COO) & International Activities, Eurobank Holdings, Stavros Ioannou, said, “Eurobank Group has always been at the forefront of innovation, driving digital transformation to enhance customer experience and operational excellence. Our journey to becoming a digital leader is built on strategic partnerships that accelerate modernisation and create seamless, future-ready solutions. Partnering with LTIMindtree, in collaboration with Fairfax Digital Services, marks a significant milestone in this journey—strengthening our IT capabilities to meet evolving customer expectations and regulatory requirements. We are excited about the future as we redefine customer experience and set new industry benchmarks with the launch of our new Delivery Center in India.”

Sanjay Tugnait, CEO Fairfax Digital Services, said, “At Fairfax Digital Services, we are proud to collaborate with Eurobank and LTIMindtree to establish this new Global Delivery Center in Pune. By embracing emerging technologies, we are driving innovation to create enhanced customer experiences and deliver strong business value. This partnership will help Eurobank navigate a rapidly evolving technology landscape and strengthen its position as a digital leader in the industry.”

Srini Rao, EVP & Chief Business Officer Europe, LTIMindtree, said, “We are thrilled to announce our partnership with Eurobank as they embark on an ambitious journey to modernize their banking infrastructure technology platform. Our expertise in cutting-edge IT services and seamless Temenos implementation services positions us uniquely to deliver innovative solutions that meet the future needs of Eurobank.”

About Eurobank Group

The Eurobank Group, consisting of Eurobank SA and its subsidiaries, is a robust financial organisation. The Group develops financial products and services, focusing on customers and their needs. It offers sophisticated choices and well-rounded services to individuals and businesses. The Eurobank Group operates with transparency, builds credibility and applies modern corporate governance practices. With presence in Greece, Cyprus, Luxembourg, Bulgaria and UK (London), the Eurobank Group counts (data as of 30 September 2024):

€99.6 billion in total assets

604 branches network in Greece and abroad

12,880 employees

About Fairfax Financial Holdings Limited

Fairfax Financial Holdings Limited is a holding company which, through its subsidiaries, is primarily engaged in property and casualty insurance and reinsurance and the associated investment management. Founded in 1985 by the present Chairman and Chief Executive Officer, Mr. V. Prem Watsa, the company is headquartered in Toronto, Canada.

About LTIMindtree

LTIMindtree is a global technology consulting and digital solutions company that enables enterprises across industries to reimagine business models, accelerate innovation, and maximize growth by harnessing digital technologies. As a digital transformation partner to more than 700 clients, LTIMindtree brings extensive domain and technology expertise to help drive superior competitive differentiation, customer experiences, and business outcomes in a converging world. Powered by 86,000+ talented and entrepreneurial professionals across more than 40 countries, LTIMindtree — a Larsen & Toubro Group company — solves the most complex business challenges and delivers transformation at scale. For more information, please visit www.ltimindtree.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250214402850/en/

Permalink

https://www.aetoswire.com/en/news/54207521

Contacts

 

Media Contacts:

Madhur Bhayana | Global Media Relations | madhur.bhayana@ltimindtree.com

Michelle Kumar | Global Media Relations | michelle.nalinikumar@ltimindtree.com

ATP Media Selects SES for Tennis Content Delivery Worldwide

 LUXEMBOURG

SES SCORE platform and hybrid distribution to power broadcasts of 58 ATP tournaments that reach a billion global fans through 70+ broadcast partners

(BUSINESS WIRE)--SES announced today a new agreement to deliver and manage video content for ATP Tour events around the world using Secure Reliable Transport (SRT) and its unique Sports Content Orchestration Enabler (SES SCORE) platform enabled by SES’s hybrid IP, fibre and satellite distribution network.

With more than 200,000 hours of live content per year from 3,200 tennis matches across various ATP Masters 1000, ATP 500 and ATP 250 tournaments, SES SCORE gives ATP Media an easy-to-use, centralized platform to manage and deliver its content. ATP Media’s 70+ broadcast partners can select from a variety of video feeds, audio, metadata and other content when creating their broadcasts with a simplified booking process.

“We wanted to give our broadcast partners unrestricted access to up to 10 Court Feeds we produce at our ATP Masters 1000 tournaments, as well as a secure method of delivering the World Feed as we transitioned away from satellite,” said Tom Copeland, Director of Technology at ATP Media. “By working with SES, we’ve created a simple, unified content orchestration and fully redundant hybrid distribution system where our partners can easily book and receive our SRT streams automatically through the SES SCORE Portal, enabling them to regionalise their coverage even further.”

“This is an important agreement, not only because of ATP Media’s status as a major and iconic professional sports media organization, but also that it showcases our unique content orchestration technology and hybrid distribution capabilities,” said Michele Gosetti, Head of Sales, Sports & Events at SES. “Our SES SCORE platform enables ATP Media to offer a single source to its broadcasters for picking various feeds and content sources – from full court views to player and coach isolation shots and more – to customize the broadcast to the tennis fans in their specific markets.”

To find out more about how SES SCORE enables management and distribution of live content, visit: https://www.ses.com/find-service/sports-organisations/ses-score

Follow us on:

Twitter | Facebook | YouTube | LinkedIn | Instagram

Read our Blogs >

Visit the Media Gallery >

About SES

SES has a bold vision to deliver amazing experiences everywhere on Earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a provider of global content and connectivity solutions, SES owns and operates a geosynchronous orbit fleet and medium earth orbit (GEO-MEO) constellation of satellites, offering a combination of global coverage and high-performance services. By using its intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners around the world. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com

About the ATP

The ATP’s mission is to serve tennis. As a governing body of the ATP Tour and Challenger Tour we entertain a billion global fans, showcase the world’s greatest players at prestigious tournaments, and inspire the game’s next generation. From the United Cup in Australia, to Europe, the Americas and Asia, the stars of the game battle for titles and PIF ATP Rankings points at ATP Masters 1000, 500 and 250 events, and Grand Slams. All roads lead to the Nitto ATP Finals, our prestigious season finale held in Turin, Italy. Featuring only the season’s best 8 singles players and doubles teams, the tournament sees the crowning of the year-end ATP World No. 1, presented by PIF, the ultimate achievement in tennis. For more information, please visit www.ATPTour.com.

About ATP Media

As the broadcast arm of the ATP Tour, ATP Media was formed in 2001 as Tennis Properties Limited; providing the centralised exploitation of media rights across the ATP Tour, host broadcast production for the Nitto ATP Finals, Next Gen ATP Finals presented by PIF, ATP Masters 1000s and world feed production for the ATP 500s and, more recently, the ATP 250s. ATP Media has unrivalled access and expertise in the full-service broadcast production of men’s professional tennis with an end to end solution for global broadcasters incorporating: rights sales, multi-platform production, a global fibre distribution network and a market leading digital archive. For more information, please visit www.atpmedia.tv.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250216860241/en/

Permalink

https://www.aetoswire.com/en/news/1702202544740

Contacts

For further information please contact:

Suzanne Ong

Communications

Tel. +352 710 725 500

suzanne.ong@ses.com

Ruler of Ras Al Khaimah, UAE, says ‘science is the bedrock upon which we build a sustainable future’ during opening address at 16th International Workshop on Advanced Materials

  Ras Al Khaimah, United Arab Emirates - Monday, 17. February 2025 AETOSWire 

HH Sheikh Saud bin Saqr Al Qasimi:  

‘Ras Al Khaimah is committed to nurturing scientific advancement and contributing to the global conversation on advanced materials’

 

His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, delivered an opening keynote address on the first day of the three-day International Workshop on Advanced Materials (IWAM), where he talked of science holding the key to building a more sustainable world and of how Ras Al Khaimah is committed to scientific advancement.

HH Sheikh Saud said: “Through the annual hosting of IWAM, Ras Al Khaimah is reaffirming its commitment to nurturing scientific advancement and contributing to the global conversation on advanced materials.

“By developing a culture of scientific enquiry and investing in advanced materials, we are laying the foundation for a brighter tomorrow. Major breakthroughs in advanced materials research have the potential to revolutionize energy production, transportation and manufacturing.”

Science is the systematic and purposeful pursuit of knowledge, the lens through which we examine the universe, HH Sheikh Saud added.

“Science must be the bedrock upon which we build a sustainable and prosperous future, with our younger generations playing an active role in furthering our pursuit of knowledge,” HH Sheikh Saud concluded.

IWAM, in its 16th year, brings together 200+ attendees from 20+ countries, including scientists, students and speakers, for lectures, discussions and poster sessions on how advanced materials are helping to shape the future. 

The forum is attended by scientists from prestigious academic institutions, such as the universities of Cambridge and Oxford (UK), and the University of California and Massachusetts Institute of Technology (MIT) (U.S.).

IWAM also sees scientists awarding the student winners of the Ras Al Khaimah Innovation and Sustainability Challenge, which comprises seven competitions to develop innovative solutions to real-life challenges.

A scientific session for high-school students also takes place during IWAM, while scientists will visit Ras Al Khaimah-based companies to highlight how advanced materials can be utilized to improve productivity.

IWAM is sponsored by Ras Al Khaimah’s Stevin Rock, one of the largest quarrying companies in the world, with a production capacity of 80 million+ tons per year.    

Permalink

https://aetoswire.com/en/news/rak17022025

Contacts

Steven McCombe

media@rakmediaoffice.ae

Venture Global, Inc. Announces Timing of Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

 ARLINGTON, Va. - Saturday, 15. February 2025 AETOSWire Print 

(BUSINESS WIRE)--Venture Global, Inc. (“Venture Global”) (NYSE: VG) announced today that it plans to issue its earnings release with respect to fourth quarter and full year 2024 financial results before market open on Thursday, March 6, 2025.

Venture Global will host a conference call for investors and analysts beginning at 9:00 am Eastern Time (ET) on March 6, 2025, to discuss fourth quarter and full year results and provide guidance for the 2025 fiscal year.

A listen-only webcast of the call and accompanying slide presentation will be available at Venture Global’s Investor Relations website HERE. After the conclusion of the webcast, a replay will be made available on the Venture Global website.

About Venture Global

Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. Venture Global’s first facility, Calcasieu Pass, commenced producing LNG in January 2022. The company’s second facility, Plaquemines LNG, achieved first production of LNG in December 2024. The company is currently constructing and developing over 100 MTPA of nameplate production capacity to provide clean, affordable energy to the world. Venture Global is developing Carbon Capture and Sequestration projects at each of its LNG facilities.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250214771737/en/

Permalink

https://www.aetoswire.com/en/news/20250214771737r1

Contacts

 

Investor Contacts:

Michael Pasquarello

IR@venturegloballng.com

Media Contacts:

Shaylyn Hynes

Press@venturegloballng.com

Elon Musk Talks ‘Tech Support’ Governance as World Leaders Champion Innovation-Driven Reforms at Dubai Summit

 DUBAI, United Arab Emirates - Friday, 14. February 2025

(BUSINESS WIRE)--Wearing a “Tech Support”-printed T-shirt, Elon Musk virtually took to the stage on the final day of the World Governments Summit in a live discussion with H.E. Omar Sultan Al Olama, UAE Minister of State for Artificial Intelligence, Digital Economy, and Remote Work Applications, to share his vision for improving government efficiency.

Musk emphasized the urgency of streamlining operations, advocating for smaller, more accountable institutions to drive efficiency and economic growth.

The World Governments Summit, held in Dubai from February 11-13, brought together global leaders and experts to address critical challenges in governance, healthcare, and trade in the 21st century.

Now in its 12th edition, the Summit unveiled a suite of insights, key results, and actionable solutions developed by top policymakers, innovators, and thought leaders from around the world.

Musk stated: “We have the rule of bureaucracy as opposed to the rule of the people” and advocated for cutting regulations and government spending to stimulate economic growth, aiming for 4-5% growth without inflation by 2026.

“The overarching goal is to lay the foundation for prosperity that will last many decades, maybe centuries,” Musk added. He stressed the importance of updating government technology, noting that many systems are outdated and inefficient, such as the manual pension system. “The U.S. government needs tech support,” he quipped.

On foreign policy, Musk stated, “America should mind its own business rather than push for regime change,” signaling a shift towards less international interference. He also stressed the need to improve basic education, pointing out the U.S.’s low ranking in the OECD.

Musk also discussed Grok 3.0, his latest AI model set to launch in 1-2 weeks, calling it “scary smart.” He added, “This might be the last time any AI is better than Grok.”

Meanwhile, Joseph Tsai, Chairman of Alibaba Group, a user and admirer of Grok, argued that the value of AI isn’t in having the smartest systems, but in their application in solving real-world problems.

He compared AI development to raising children, emphasizing that not everyone needs the “smartest child.” He predicts that more resources will shift towards practical applications, leveraging open-source tools, which democratize AI development. He added: “Companies big and small can now develop AI together and contribute to the power of AI.”

Beyond AI, both Arvind Krishna, CEO of IBM, and Sundar Pichai, CEO of Google, said they looked forward to the imminent age of quantum computing, which they believe will spearhead the world into a new era.

Pichai said: “Google’s quantum computing performed a computation in five minutes that would take the fastest supercomputer over 10 septillion years.” He compared its current state to AI in the 2010s, predicting practical applications within 5-10 years.

Pichai added that for governments: “It’s too early to regulate the technology, but I think it’s important to come to a good understanding of it and then start preparing for it.”

Technology as the enabler of the new age of healthcare and education

Public healthcare systems also require innovation and new policies, argued experts at the Summit. Addressing key challenges in healthcare, Pascal Soriot, CEO of AstraZeneca, encouraged governments to develop policies that enable early disease diagnostics, improve accessibility, and encourage population-wide adoption.

Soriot stated: “Seventy-five percent of deaths come from diseases that are preventable, yet governments only spend 3% of healthcare budgets on prevention and early diagnosis.” He added that diagnostic centers should run 24/7 to reduce costs and increase accessibility.

He highlighted AI’s role in transforming healthcare, noting that it is already enhancing early diagnostics, such as lung cancer detection from X-rays, and improving efficiency in drug development. While skepticism exists around AI's role in drug design due to limited biological data, its potential in healthcare is promising.

“We are not far away from the days when a simple blood test would enable early diagnostics of cancer at a relatively low cost,” Soriot concluded.

Public-private partnerships and innovative healthcare models could further improve accessibility and cost-efficiency, helping transform global healthcare systems.

This applies beyond just healthcare. Mike Sicilia, Executive Vice President of Oracle, stated: “At the heart of every AI strategy is a data strategy. Helping governments vectorize and aggregate the data is the first step in applied AI, particularly when tailoring it to specific citizen services.”

AI applications in education were also a major focus at the Summit. David Baszucki, CEO of Roblox, explored the potential of AI in educating young users through interactive experiences on the platform. He also emphasized the importance of balancing social connectivity and safety on digital platforms.

He added: “We are at a place where it is way beyond what we imagined. In 20 years, I’m expecting an amazing amount of learning on the platform—for instance, interacting with virtual historical characters.”

Global economic challenges and financial cooperation

In parallel discussions, Kristalina Georgieva, Managing Director of the IMF, alongside finance ministers, international officials, and economic experts, explored the challenges facing the multilateral cooperation system, including rising nationalist and geopolitical trends, climate change, and economic inequality.

Speakers highlighted the need for innovative financing mechanisms and an expanded global financial safety net to address economic crises and support developing countries.

They also underlined the role of technology in strengthening financial systems, aligning global networks to protect against economic crises, and building sustainable frameworks for debt management in vulnerable economies.

For more information, visit worldgovernmentsummit.org.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250214293771/en/

Permalink

https://www.aetoswire.com/en/news/1402202544726

Contacts

Anna Lagutina

a.lagutina@mcgroup.com

 

Five-Time Olympic Medalist Gabby Thomas Joins Amazfit as Athlete Ambassador

 

MILPITAS, Calif. -

Amazfit becomes Thomas’ first Smartwatch Partner

(BUSINESS WIRE)--Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), is proud to announce five-time Olympic Medalist and fashion icon, Gabby Thomas, as the latest ambassador to join the brand's growing roster of elite athletes. As part of the four-year partnership, Thomas will wear Amazfit smartwatches both on the track during training and in competition, and off the track to monitor sleep and recovery. Moreover, through the Zepp app-based food log, Gabby will have easy access to nutrition-tracking as well.

As the 200m, 4x100m and 4x400m gold medalist, Thomas left the 2024 Paris Olympics as the most decorated U.S. track and field athlete at the Games. Additionally, she holds multiple Diamond League titles and took home two additional Olympic medals - 200m (bronze) and 4x100m (silver) - at the 2020 Tokyo Games. The partnership with Amazfit is Thomas’ first with a smartwatch and gives credence to the benefits data can play on athletic performance.

“I’m really excited to partner with Amazfit because, for me, the little things make all the difference,” said Thomas. “As an athlete, this is the exact type of partnership that will help me continue to get better. It's so important to have objective data on my body—whether it’s tracking my heart rate during a workout, seeing how well I’ve recovered, or understanding how much quality sleep I’m getting. Having a reliable smart wearable brand like Amazfit in my corner is a game-changer."

As part of this exciting partnership, Thomas will enhance her training by incorporating Amazfit's smart wearables analysis into her preparation and recovery to improve performance and help break future records. She will also provide insights and feedback to Amazfit’s development and design teams on product future features and styles.

"We are honored to have Gabby join the Amazfit team," said Wayne Huang, Founder & CEO, Zepp Health. "Her remarkable athletic career and passion for style align closely with our mission to unlock the limits of human potential to ‘Discover Amazing.’ Through this partnership, we will continue to empower athletes to unleash their full potential by rewriting the record books utilizing our advanced smart wearables ecosystem."

Amazfit is committed to creating products that empower holistic health and well-being, and that healthy living requires balance across four key pillars of wellness: physical fitness, sleep, mindfulness and nutrition. Amazfit’s diverse product portfolio includes Active, Cheetah and T-Rex series performance smartwatches, Helio smart ring and the Zepp App, all designed to help athletes and health enthusiasts track and enhance their holistic health. The Zepp App’s latest Food Log feature offers athletes like Thomas an unparalleled ability to bridge the gap between nutrition and fitness, ensuring peak performance and optimal recovery. Whether monitoring heart rate, tracking sleep cycles, or logging meals, Amazfit provides the insights needed to maintain a well-rounded approach to health.

Thomas joins a growing list of Amazfit athletes, including HYROX World Champions Meg Jacoby and Hunter McIntyre, Padel star Bea González and Olympians Morgan Pearson (triathlon) and Yemaneberhan "Yeman" Crippa (5k & 10k).

Explore the full range of Amazfit smart wearables and experience innovation that elevates performance, recovery, and precision at www.amazfit.com.

For more information, please visit Amazfit.com and follow us on Facebook, Instagram, Twitter and YouTube.

About Amazfit

Amazfit, a leading global smart wearable brand focused on health and fitness, is part of Zepp Health (NYSE: ZEPP), a health technology company. Offering a wide selection of smartwatches and bands, Amazfit's brand tagline "Discover Amazing", encourages individuals to break their barriers, and exceed expectations while finding joy in every moment.

Amazfit is powered by Zepp Health's proprietary health management platform that delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. With outstanding craftsmanship, Amazfit smartwatches have won many design awards, including the iF Design Award and the Red Dot Design Award.

Launched in 2015, Amazfit is today embraced by millions of users. Its products are available in more than 90 countries across the Americas, EMEA, and APAC regions. For more information about Amazfit, visit www.amazfit.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250213824479/en/

Permalink

https://www.aetoswire.com/en/news/20250213824479r1

Contacts

 

MEDIA CONTACT

Mary Thompson Woodbury

mary.woodbury@zepp.com

 

Kao Corporation Discloses the "Board of Directors' Opinion on Shareholder Proposal and Kao’s Strategy to Enhance Corporate Value"

 TOKYO - Friday, 14. February 2025 AETOSWire 

(BUSINESS WIRE)--Kao Corporation (TOKYO:4452) disclosed its opinion on February 14, 2025, regarding the shareholder proposals submitted by Oasis Japan Strategic Fund Ltd. (“Oasis”) for the 119th Annual General Meeting of Shareholders.

Notice Regarding the Board of Directors' Opinion on a Shareholder Proposals

Additionally, the company has published its response to a statement issued by Oasis in April 2024 in a document titled "Board of Directors' Opinion on Shareholder Proposal and Kao’s Strategy to Enhance Corporate Value."

Board of Directors' Opinion on Shareholder Proposal and Kao's Strategy to Enhance Corporate Value

Kao will continue to pursue highly transparent and effective governance, while at the same time implementing the K27 strategy and making every effort to increase its corporate value.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250214292652/en/

Permalink

https://www.aetoswire.com/en/news/54206762

Contacts

 

Media inquiries should be directed to:

Public Relations

Kao Corporation

corporate_pr@kao.com

Sandvine Clears Major Milestones Enabling Close of Comprehensive Restructuring

 PLANO, Texas - Friday, 14. February 2025

Sandvine clears final milestones enabling its emergence into an AI-driven software company conducting business in democracies, serving telcos, enterprises, managed service providers and cloud providers

(BUSINESS WIRE)--Sandvine Corporation and certain of its affiliates and subsidiaries (“Sandvine” or the “Company”) today announced that on January 30, 2025, it received formal approval from the Ontario Superior Court of Justice (Commercial List) for its previously announced comprehensive restructuring, clearing the path to emerge from protection under the Companies’ Creditors Arrangement Act (“CCAA”) through a sale of its operations to a set of well-capitalized, newly formed entities. In addition, on February 12, 2025, the Company received recognition and enforcement of the Canadian Court’s order within the United States. The Company plans to execute the restructuring transaction and launch its new brand in the coming weeks.

“Today we announce an important milestone in the Company’s business realignment. We are confident that with the overwhelming support of our investors, customers, and employees, we are positioned for continued success as a technology solutions provider of choice for leading telecom and communications companies across the democratic world,” said Carney Hawks, Chairman of the Board of Sandvine. “We look forward to entering this next chapter, which we are confident will be marked by innovation in best-in-class technology, strong business and financial performance, and outstanding customer service.”

The Company will continue to work closely with stakeholders while focusing on promoting internet freedom and digital rights.

About Sandvine

Sandvine, the App QoE company, offers a portfolio that helps service providers deliver high quality, optimized experiences to consumers and enterprises. Service providers around the world are dealing with the fact that the internet is going dark, due to more encryption in applications and transport protocols. The Sandvine portfolio classifies more than 95% of network traffic into applications, application categories, and content categories, providing QoE scores and persona-guided workflows that address business problems quickly and efficiently. To learn how Sandvine solutions empower service providers globally to analyze, optimize, and monetize application experiences, follow Sandvine on Facebook, LinkedIn, and Twitter.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250213537768/en/

Permalink

https://www.aetoswire.com/en/news/20250213537768r1

Contacts

 

Media and NGO Contact

pro-sandvine@prosek.com

Customer, Partner, and Supplier Contact

contactus@sandvine.com

 

Pine Island New Energy Partners and Type One Energy Announce Collaboration to Mature Fusion Energy Supply Chain

 KNOXVILLE, Tenn. - Thursday, 13. February 2025

(BUSINESS WIRE)--Pine Island New Energy Partners (PINEP), a private equity firm, and Type One Energy, the leading stellarator fusion company in the market, today announced their strategic collaboration to accelerate the maturation of a more robust supply chain for the fusion energy industry.

As the global fusion sector moves aggressively toward commercialization, the need to refine and scale the supply of specialized components and advanced manufacturing capabilities is more urgent than ever. Through this collaboration, PINEP can better provide the capital and management assistance needed to enable these fusion industry supplier chain companies to meet the needs of the growing fusion industry. The role of Type One Energy is that of an advisory institutional operating partner, working together with PINEP to identify and evaluate companies which have the technology and expertise, such as manufacturing high-temperature superconductors, providing advanced materials, and performing precision manufacturing, to grow and succeed in this emerging market.

“We are excited to partner with Type One Energy to help scale the companies that will enable the commercial fusion industry to thrive,” said Chris Good, Managing Partner at Pine Island New Energy Partners. “Our strategy focuses on growth-stage supply chain companies that produce critical technologies serving both fusion and the broader electrification markets. By working with Type One Energy’s technical team, we can better evaluate and support companies that will be crucial to this transformative industry.”

This announcement follows the recent announcement that the Tennessee Valley Authority (TVA) and Type One Energy will jointly develop and evaluate a fusion power plant project in the Tennessee Valley region, with TVA building and operating the plant using Type One Energy stellarator fusion power technology. The company’s collaboration with PINEP will strengthening the supply chain necessary to build Infinity Two as well as scale the broader fusion industry to meet the more than $1T/year global market demand for 20,000 GW of safe, abundant, clean fusion energy.

“To bring fusion energy to the global energy markets, we need to cultivate an efficient, reliable, and innovative world-wide supply chain,” said Chris Mowry, CEO of Type One Energy. “By partnering with PINEP, we can combine our fusion industry knowledge with their expertise to address this challenge in a more practical way.”

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250213421850/en/

Permalink

https://www.aetoswire.com/en/news/1302202544655

Contacts

Media Contacts:

For Type One Energy:

Andrea Schneibel

Type One Energy | Marketing and Communications

608-616-5965

andrea.schneibel@typeoneenergy.com

 

Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis

  ZUG, Switzerland - Friday, 14. February 2025 AETOSWire

Ad hoc announcement pursuant to Art. 53 LR

    This approval from the European Commission is based on robust results from the phase III OLYMPIA and ARCADIA clinical trial programs, showing that Nemluvio has the potential to address the significant unmet needs of patients with atopic dermatitis and prurigo nodularis1-3
    There is a need for new treatment options for atopic dermatitis and prurigo nodularis to effectively relieve the signs and symptoms such as persistent itch, skin lesions and poor sleep quality4-8
    Nemluvio is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis, and fibrosis in prurigo nodularis5,8-10
    Nemluvio is the first monoclonal antibody in Galderma’s portfolio of innovative, science-based products, which span the full spectrum of the fast-growing dermatology market

 

(BUSINESS WIRE)--Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now approved for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.11

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213843444/en/

 

“Throughout Galderma’s four decades in dermatology we have consistently worked to meet the needs of patients and deliver first-in-class treatment options. This has been exemplified through the clinical and regulatory success achieved with our unique monoclonal antibody, Nemluvio. As the first biologic treatment in our Therapeutic Dermatology portfolio, Nemluvio shows our commitment to advancing dermatology by expanding into new areas of need.”

FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER
GALDERMA

 
    

 

Nemluvio is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31.9 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis, and fibrosis in prurigo nodularis.5,8-10 It is also the first and only biologic approved for atopic dermatitis and prurigo nodularis with four-week dosing intervals from the start of treatment.11

This approval is based on results from the phase III ARCADIA and OLYMPIA clinical trial programs, in which Nemluvio significantly improved itch, skin lesions and sleep disturbance, in patients with moderate-to-severe atopic dermatitis and adults with prurigo nodularis, respectively.1-3

Results from the ARCADIA 1 and ARCADIA 2 trials demonstrated that patients treated with Nemluvio, administered subcutaneously every four weeks in combination with background topical corticosteroids, with or without topical calcineurin inhibitors (+TCS/TCI), showed statistically significant improvements on skin clearance in both co-primary endpoints at Week 16, when compared to placebo +TCS/TCI.1 The trials also met all key secondary endpoints, confirming significant responses on itch as early as Week 1 and statistically significant improvements in sleep disturbance.1

Both co-primary endpoints were also met in the OLYMPIA 1 and OLYMPIA 2 clinical trials, where Nemluvio monotherapy demonstrated significant and clinically meaningful improvements on itch and skin lesions at Week 16, when compared to placebo.2,3 The trials met all key secondary endpoints, showing rapid reduction in itch due to prurigo nodularis and sleep disturbance within four weeks of treatment initiation.2,3

Nemluvio was well tolerated in all trials, and its safety profile was generally consistent with earlier data, and between trials.1-3

 

“Atopic dermatitis and prurigo nodularis can severely impact quality of life due to the associated debilitating symptoms, including chronic itch, skin lesions, poor sleep quality and mental health conditions. With this approval, patients in the EU have a new treatment option, which extensive data has shown can help to safely, quickly, and effectively ease the key symptoms of these diseases and therefore the burden on patients’ lives.”

PROFESSOR DIAMANT THAÇI
LEAD INVESTIGATOR OF THE ARCADIA STUDIES IN EUROPE
UNIVERSITY OF LUBECK, GERMANY

 
    

 

 

“Nemolizumab’s benefits have been demonstrated in its comprehensive clinical trial programs in both atopic dermatitis and prurigo nodularis, including the OLYMPIA 1 and 2 studies, which make up the largest completed pivotal program in prurigo nodularis to date. These clinical data, plus its first-in-class mechanism of action and convenient dosing schedule, make it an important new therapeutic solution for dermatologists to support their patients.”

PROF. SONJA STÄNDER
LEAD INVESTIGATOR OF THE OLYMPIA STUDIES IN EUROPE
UNIVERSITY HOSPITAL MÜNSTER, GERMANY

 
    

 

Nemluvio is also approved by the U.S. Food and Drug Administration for the treatment of atopic dermatitis and prurigo nodularis.12 It is under review for the treatment of both diseases by several additional regulatory authorities around the world, including Canada, Brazil, and South Korea, and via the Access Consortium framework in countries such as Australia, Singapore and Switzerland. Further submissions to other regulatory authorities are ongoing.

As previously communicated, peak sales of Nemluvio are expected to reach more than 2 billion USD (expected beyond the 2023-2027 mid-term guidance period). Galderma anticipates Nemluvio to approach ‘blockbuster’ net sales run-rate by the end of 2027.

Media can find more information about atopic dermatitis and prurigo nodularis here.

About Nemluvio

Nemluvio was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan and Taiwan. In Japan, nemolizumab is marketed as Mitchga® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients.13,14

About the ARCADIA clinical trial program1,15,16

The ARCADIA program included two identically designed, pivotal phase III clinical trials, which enrolled more than 1,700 patients – ARCADIA 1 and ARCADIA 2.

These global, randomized, multicenter, double-blind, placebo-controlled phase III clinical trials evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks compared to placebo (both administered with background topical corticosteroids with or without topical calcineurin inhibitors).

The trials were conducted in adolescent and adult patients (12 years and over) with moderate-to-severe atopic dermatitis for an initial treatment phase of 16 weeks. Patients who responded to treatment (defined as patients who achieved an investigator’s global assessment score of clear (0) or almost clear (1), or a 75% or greater improvement in the eczema area and severity index score) were then re-randomized to a maintenance treatment phase for up to 48 weeks.

About atopic dermatitis

Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease, characterized by persistent itch and recurrent skin lesions.5,17,18 It is the most common inflammatory skin disease, impacting almost four times more people than psoriasis.5,19 It affects approximately 10 to 40 million people in the European Union, with up to 66% of adults suffering with a moderate-to-severe form of the condition.20,21 While currently available treatments may improve some signs and symptoms of the disease, many patients do not respond optimally to approved therapies and do not experience itch relief and clear skin to the same degree.5-8

About the OLYMPIA clinical trial program2,3,22,23

The OLYMPIA program included two identically designed, pivotal phase III clinical trials which enrolled 560 patients – OLYMPIA 1 and OLYMPIA 2. This is the largest clinical trial program conducted in prurigo nodularis to date, and the only program to include a long-term extension study.

These global, randomized, double-blind, placebo-controlled phase III clinical trials assessed the efficacy and safety of nemolizumab monotherapy compared with placebo in patients at least 18 years of age with moderate-to-severe prurigo nodularis over a 16- or 24-week treatment period for OLYMPIA 2 and OLYMPIA 1, respectively.

About prurigo nodularis

Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas.24-26 It is estimated to affect between 7-111 people per 100,000 in the European Union depending on the country.27,28 The majority of patients report that the persistent itch negatively impacts their quality of life.29 Furthermore, the intense itch associated with prurigo nodularis results in significant sleep disturbance and further contributes to reduced quality of life.30,31

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

    Silverberg J, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 & 2): results from two replicate double-blinded, randomised controlled phase 3 trials. Lancet. 2024;404(10451):445-460. doi: 10.1016/S0140-6736(24)01203-0
    Kwatra SG, et al. Placebo-controlled phase III trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389:1579-89. doi: 10.1056/NEJMoa2301333
    Ständer S, et al. Nemolizumab in Patients with Moderate-to-Severe Prurigo Nodularis: A Randomized Controlled Phase 3 Trial. JAMA Derm. 2024;160. doi: 10.1001/jamadermatol.2024.4796
    Chisolm SS. A Review of the Current Management and Burden of Prurigo Nodularis in the United States. AJMC. 2023; 2023;29(suppl 5):S63-S72. doi.org/10.37765/ajmc.2023.89366
    Langan SM, et al. Atopic dermatitis [published correction appears in Lancet. 2020;396(10253):758]. Lancet. 2020;396(10247):345-360. doi:10.1016/S0140- 6736(20)31286-1
    Lobefaro F, et al. Atopic Dermatitis: Clinical Aspects and Unmet Needs. Biomedicines. 2022;10:2927. doi:10.3390/biomedicines10112927
    Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol. 2019;46(12):1053-1101. doi:10.1111/1346-8138.15090
    Kwatra SG, Misery L, Clibborn C, Steinhoff M. Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics. Clin Transl Immunology. 2022;11(5):e1390. doi:10.1002/cti2.1390
    Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173-182. doi:10.1016/j.jaci.2019.08.013
    Bewley A, et al. Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments. Dermatol Ther (Heidelb). 2022;12(9):2039–2048. doi:10.1007/s13555- 022-00782-2
    Nemluvio. EU Summary of Product Characteristics 2025
    NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P.; August 2024
    Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Accessed February 2025
    Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Accessed February 2025
    ClinicalTrials.Gov. Efficacy & Safety of Nemolizumab in Subjects With Moderate- to-Severe Atopic Dermatitis (NCT03985943). Available online. Accessed February 2025
    ClinicalTrials.Gov. Efficacy & Safety of Nemolizumab in Subjects With Moderate- to-Severe Atopic Dermatitis (NCT03989349). Available online. Accessed February 2025
    Yang G, et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020;21(8):2867. doi: https://doi.org/10.3390/ijms21082867
    Ständer S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136-1143. doi:10.1056/NEJMra2023911
    Raharja A, et al. Psoriasis: a brief overview. Clin Med (Lond). 2021;21(3):170-173. doi: 10.7861/clinmed.2021-0257
    Luger, T, et al. Clinical and Humanistic Burden of Atopic Dermatitis in Europe: Analyses of the National Health and Wellness Survey. Dermatol Ther (Heidelb). 2022;12:949–969. https://doi.org/10.1007/s13555-022-00700-6
    Oisín S, et al. 545 - Prevalence of moderate and severe atopic dermatitis in Ireland: a cross-sectional, real-world study of a secondary care population. BJD. 2024;190(S2):ii43–ii44. https://doi.org/10.1093/bjd/ljad498.045
    ClinicalTrials.Gov. An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (NCT04501679). Available online. Accessed February 2025
    ClinicalTrials.Gov. Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501666). Available online. Accessed February 2025
    Huang AH, et al. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559-1565. doi:10.1016/j.jaad.2020.04.183
    Pereira MP, et al. European Academy of Dermatology and Venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059-1065. doi:10.1111/jdv.14570
    Ständer S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5(4):e42. doi:10.1097/itx.0000000000000042
    Ryczek A, et al. Prevalence of Prurigo Nodularis in Poland. Acta Derm Venereol. 2020;100:adv00155. doi: 10.2340/00015555-3518
    Ständer, S, et al. Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: A Claims Database Analysis. Acta Dermato-Venereologica. 2020;100(18):1–6. https://doi.org/10.2340/00015555-3655
    Todberg T, et al. Treatment and burden of disease in a cohort of patients with prurigo nodularis: a survey-based study. Acta Derm Venereol. 2020;100(8):adv00119. doi:10.2340/00015555-3471
    Joel MZ, et al. Risk of itch-induced sleep deprivation and subsequent mental health comorbidities in patients with prurigo nodularis: A population-level analysis using the Health Improvement Network. E-poster presented at EADV 2023. Abstract available online
    Kwatra SG. Breaking the itch–scratch cycle in prurigo nodularis. N Engl J Med. 2020;382(8):757-758. doi:10.1056/NEJMe1916733

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250213843444/en/

Permalink
https://www.aetoswire.com/en/news/1402202544700

Contacts

For further information:

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Sébastien Cros
Corporate Communications Director
sebastien.cros@galderma.com
+41 79 529 59 85

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43

MAG participe à l’Expo Blackburn Dubai Property et présente son projet de développement haut de gamme aux acheteurs britanniques

  Londres, Royaume-Uni - jeudi, 13. février 2025 AETOSWire 

MAG, l'un des principaux promoteurs immobiliers des Émirats Arabes Unis, participera à l’Expo Blackburn Dubai Property, qui se tiendra les 22 et 23 février au Stanley House Hotel & Spa, au Royaume-Uni. Le promoteur présentera son projet phare, The Ritz-Carlton Residences, Dubai, Creekside, qui fait partie du Keturah Resort, offrant une opportunité unique d'un style de vie inégalé avec un service et des commodités sans pareil.

 

Le secteur immobilier de Dubaï enregistre constamment une forte croissance, stimulée par les particuliers fortunés à la recherche de projets de développement luxueux. Grâce à près de 740 résidences de marque dans le monde, un chiffre prévu de doubler d'ici 2031, Dubaï joue un rôle clé, avec 140 projets en cours. Au premier semestre 2024, les résidences de marque représentaient 7,2 % de toutes les transactions immobilières, générant 7,8 milliards de dollars, soit 12,6 % de la valeur totale des transactions de l'année dernière. Ces propriétés offrent des prix premium et des rendements locatifs élevés, ce qui en fait une option d'investissement attrayante.

Situées au sein du Keturah Resort, le premier complexe hôtelier entièrement certifié bien-être de la région MENA, The Ritz-Carlton Residences, Dubai, Creekside, comprend 200 résidences réparties dans sept bâtiments et 12 villas, chacune dotée d'un amarrage exclusif pour yacht pour les résidents. Les propriétaires bénéficieront d'une gamme impressionnante d'équipements de classe mondiale, y compris un centre de bien-être, un Clubhouse avec un club privé pour membres, un club pour femmes, un club pour enfants, des restaurants gastronomiques et étoilés dans le guide Michelin, une esplanade de 550 mètres, des espaces commerciaux durables et axés sur les produits bio, un parking privé 24h/24 avec voiturier, et une communauté sécurisée offrant des vues uniques sur la réserve naturelle, le Burj Khalifa, le port de Dubaï Creek et Meydan.

David James, Directeur des Ventes chez MAG, a déclaré : « Le secteur immobilier des Émirats Arabes Unis reste solide, et bénéficie d’un intérêt soutenu de la part des investisseurs internationaux, en particulier du Royaume-Uni. En présentant le Keturah Resort à l’Expo Blackburn Dubai Property, nous avons l'opportunité de mettre en valeur ses caractéristiques uniques et d’offrir une opportunité haut de gamme destinée à remodeler le paysage immobilier de la région MENA ».

Le projet est situé sur le Dubai Creek, offrant un accès aisé au centre-ville de Dubaï, au Dubai International Financial Centre et à l'aéroport international de Dubaï.

Pour plus d'informations, veuillez consulter le site électronique suivant : www.theresidencescreeksidedubai.com.

Clause de non-responsabilité juridique

The Ritz-Carlton Residences, Dubai, Creekside, ne sont ni détenues, ni développées, ni vendues par The Ritz-Carlton Hotel Company, LLC ou ses sociétés affiliées (« Ritz-Carlton »). MAG of Life FZ-LLC utilise les marques Ritz-Carlton sous licence de Ritz-Carlton, qui n'a pas confirmé l'exactitude des déclarations ou des représentations énoncées dans ce document.

Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

Permalink

https://www.aetoswire.com/fr/news/1302202544626

Contacts

Khaled Abu Hishme

khaled@cbpr.me

Trident et le ministère des Postes, des Télécommunications et des Technologies numériques de la République démocratique du Congo signent un accord pour la mise en œuvre du Système national d’identité numérique

 

SINGAPOUR, 12 févr. 2025 (GLOBE NEWSWIRE) -- Trident Digital Tech Holdings Ltd (« Trident » ou la « Société », NASDAQ : TDTH), un catalyseur majeur de la transformation numérique dans les services d’optimisation technologique et d’activation Web 3.0 basé à Singapour, a annoncé aujourd’hui la signature d’un accord de mise en œuvre avec le ministère des Postes, des Télécommunications et des Technologies numériques de la République démocratique du Congo (« RDC » ou la « République »). Cet accord marque le début du déploiement du Système national d’identité numérique.

Cet accord de collaboration préliminaire détermine le lancement opérationnel d’une plateforme globale d’identification et d’authentification numérique en RDC. Il officialise la collaboration initiale entre Trident et la République démocratique du Congo, qui évolue de la planification stratégique à l’exécution contractuelle.

Cet accord décrit des livrables spécifiques, notamment le développement et le déploiement d’un système intégré de vérification et d’authentification de l’identité numérique basé sur une infrastructure sécurisée pour la fourniture de services gouvernementaux.

En outre, ce système intégrera de solides mesures de protection des données alignées sur les normes internationales afin de garantir la sécurité et la confidentialité des informations des citoyens. Ces éléments fondamentaux visent à révolutionner les interactions entre les citoyens et le gouvernement et marquent ainsi une étape majeure vers une nation numériquement intégrée. Cette technologie profitera également aux citoyens en améliorant l’efficacité et la sécurité des services gouvernementaux, tout en garantissant le contrôle et le consentement des utilisateurs.

Déclarations de l’équipe de direction

Soon Huat Lim, fondateur, président et directeur général de Trident, a déclaré :

« La signature de cet accord représente une étape cruciale dans notre mission de fournir aux citoyens de la RDC des services d’identité numérique sécurisés et accessibles. En travaillant directement avec le ministère des Postes, des Télécommunications et des Technologies numériques, nous mettrons en œuvre des systèmes avancés de vérification et d’authentification de l’identité numérique qui serviront de pierre angulaire à la transformation numérique de la RDC. Cette phase de mise en œuvre se concentrera sur la construction d’une infrastructure robuste afin que chaque citoyen puisse accéder en toute sécurité aux services gouvernementaux grâce à une identité numérique vérifiée. »

Il a ajouté :

« Les systèmes que nous développons établiront de nouvelles normes pour la gouvernance numérique en Afrique, tout en créant un modèle reproductible pour les pays en développement. Ce partenariat est un parfait exemple de la manière dont une technologie innovante peut être exploitée pour générer des changements significatifs dans le quotidien des gens. »

Augustin Kibassa Maliba, ministre des Postes, des Télécommunications et des Technologies numériques de la RDC, a déclaré :

« Le système d’identité numérique est un pilier fondamental de la modernisation de notre pays par le biais de la transformation numérique. Avec Trident, nous serons en mesure de fournir à nos citoyens un accès sécurisé et efficace aux services gouvernementaux, tout en protégeant leurs données personnelles grâce aux progrès de la technologie blockchain. Ce partenariat démontre notre engagement à tirer parti de solutions innovantes dans l’intérêt de tous les Congolais. La mise en œuvre de cette transformation numérique se traduit par la construction d’infrastructures, mais aussi par la création de nouvelles opportunités de croissance économique et d’inclusion sociale. »

À propos de Trident

Basé à Singapour, Trident est un catalyseur pionnier de la transformation numérique dans les secteurs de l’optimisation numérique, les services technologiques et l’activation Web 3.0 à l’échelle mondiale. Cette société propose des solutions numériques commerciales et technologiques conçues pour optimiser l’expérience de ses clients auprès de leurs utilisateurs finaux en favorisant l’adoption du numérique et le libre accès.

Tridentity, son produit phare, est une solution d’identité innovante et hautement sécurisée basée sur la blockchain, conçue pour fournir des capacités d’authentification unique sécurisées aux systèmes tiers intégrés dans divers secteurs. Tridentity entend proposer des fonctionnalités de sécurité inédites afin de garantir la protection des informations sensibles et prévenir les menaces potentielles, promettant ainsi une nouvelle ère sécurisée dans le paysage numérique mondial en général, en Asie du Sud-Est, etc.

Au-delà de Tridentity, la mission de Trident est de devenir le leader mondial de l’activation Web 3.0, en connectant notamment les entreprises à une plateforme technologique fiable et sécurisée, avec des expériences client sur mesure et optimisées.

Clause de non-responsabilité

La présente annonce contient des « déclarations prospectives » (« forward-looking statements ») au sens des dispositions de la « sphère de sécurité » (« safe harbor ») du Private Securities Litigation Reform Act de 1995 des États-Unis. Ces déclarations prospectives peuvent être identifiées par l’emploi de termes tels que « sera », « s’attend », « prévoit », « entend », « futur », « a l’intention », « planifie », « croit », « estime », « susceptible de » et d’autres expressions de même sens. La Société peut également faire des déclarations prospectives écrites ou orales dans ses rapports périodiques à la Securities and Exchange Commission des États-Unis (la « SEC »), dans son rapport annuel aux actionnaires, dans des annonces et autres documents écrits, ainsi que dans des déclarations orales faites par ses dirigeants, administrateurs ou employés à des tiers. Les déclarations ne relevant pas de faits historiques, y compris les déclarations concernant les convictions, les projets et les attentes de la Société, constituent des déclarations prospectives. Les déclarations prospectives impliquent des risques et des incertitudes inhérents, y compris la possibilité qu’un accord définitif ne soit pas conclu comme le prévoit l’accord de collaboration préliminaire évoqué dans la présente annonce, et la possibilité que le système e-GOV ne se concrétise pas comme le prévoit l’accord de collaboration préliminaire ou un accord définitif éventuellement conclu. En raison d’un certain nombre de facteurs, les résultats réels pourraient différer sensiblement de ceux contenus dans des déclarations prospectives, y compris, sans toutefois s’y limiter, les éléments suivants : les stratégies, le développement commercial futur, la situation financière et les résultats d’exploitation de la Société ; la croissance attendue du marché des solutions numériques ; les évolutions politiques, économiques, sociales et juridiques dans les juridictions où la Société opère ou dans lesquelles la Société a l’intention de développer ses activités et ses opérations ; la capacité de la Société à maintenir et à améliorer sa marque. De plus amples informations concernant ces risques et d’autres risques sont incluses dans les documents déposés par la Société auprès de la SEC. Toutes les informations contenues dans la présente annonce sont fournies à la date des présentes, et la Société décline toute obligation de mettre à jour les déclarations prospectives, sauf si la loi applicable l’exige.

Contacts investisseurs et médias

Relations avec les investisseurs
Robin Yang, Associé
ICR, LLC
E-mail : investor@tridentity.me 
Téléphone : +1 (212) 321-0602

Relations avec les médias
Brad Burgess, Vice-président principal
ICR, LLC
E-mail : Brad.Burgess@icrinc.com 

Une photo accompagnant la présente annonce est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/1627fdde-b97d-48f2-b2b9-f50149c37570

Copyright © 2025 GlobeNewswire, Inc.